v3.7.0.1
Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Revenue:    
Tc 99m tilmanocept sales revenue $ 0 $ 8,800
Tc 99m tilmanocept license revenue 0 254,050
Grant and other revenue 580,030 685,635
Total revenue 580,030 948,485
Cost of goods sold 0 1,489
Gross profit 580,030 946,996
Operating expenses:    
Research and development 705,274 2,072,271
Selling, general and administrative 3,022,434 2,633,126
Total operating expenses 3,727,708 4,705,397
Loss from operations (3,147,678) (3,758,401)
Other (expense) income:    
Interest income, net 24,112 757
Equity in loss of R-NAV, LLC 0 (12,239)
Change in fair value of financial instruments 140,485 1,125,359
Loss on extinguishment of debt (1,314,102) 0
Other, net (21,604) (37,292)
Total other (expense) income, net (1,171,109) 1,076,585
Loss before income taxes (4,318,787) (2,681,816)
Benefit from income taxes 1,454,172 0
Loss from continuing operations (2,864,615) (2,681,816)
Discontinued operations, net of tax effect:    
Loss from discontinued operations (255,861) (1,004,433)
Gain on sale 88,701,501 0
Net income (loss) 85,581,025 (3,686,249)
Less loss attributable to noncontrolling interest (202) (241)
Net loss attributable to common stockholders $ 85,581,227 $ (3,686,008)
Income (loss) per common share (basic):    
Continuing operations $ (0.02) $ (0.02)
Discontinued operations 0.55 0
Attributable to common stockholders $ 0.53 $ (0.02)
Weighted average shares outstanding (basic) 160,376,476 155,308,094
Income (loss) per common share (diluted):    
Continuing operations $ (0.02) $ (0.02)
Discontinued operations 0.54 0
Attributable to common stockholders $ 0.52 $ (0.02)
Weighted average shares outstanding (diluted) 164,871,955 155,308,094

Source